Stingray Cartilage (Dasyatis pastinaca)

Stingray cartilage from Dasyatis pastinaca contains bioactive phospholipase A2 enzymes and sulfated glycosaminoglycans that drive its studied biological effects. These compounds demonstrate preliminary antimicrobial and selective cytotoxic activity in laboratory settings, though no clinical trials in humans have been conducted.

Origin & History

Stingray cartilage is derived from the skeletal tissue of Dasyatis pastinaca (common stingray), a cartilaginous fish found in Mediterranean waters. The cartilage contains bioactive proteins including phospholipases A2 and chitinase enzymes, though extraction methods and standardization processes for commercial supplements are not detailed in available research.

Historical & Cultural Context

No information regarding traditional medicine use of stingray cartilage is provided in the available research literature. The search results focus exclusively on modern biomedical research rather than historical or ethnobotanical applications.

Health Benefits

• May exhibit antimicrobial properties against Gram-positive bacteria through phospholipase A2 activity (preliminary lab evidence only, PMID: 22956299)
• Shows selective cytotoxic effects against HL60 leukemia cells in laboratory studies while sparing healthy cells (in vitro evidence only, PMID: 29104260)
• Contains chitinase enzyme with dose-dependent activity (50-200 nmol/mL·h) that may contribute to antimicrobial effects (laboratory evidence only)
• Demonstrated no cytotoxicity to healthy lymphocytes or mesenchymal stem cells in cell culture studies (preliminary safety data)
• Related stingray-derived products (liver oil) showed wound healing in animal models, though not specific to cartilage (animal evidence only)

How It Works

Phospholipase A2 (PLA2) enzymes isolated from Dasyatis pastinaca cartilage hydrolyze phospholipid membranes of bacterial cell walls, disrupting membrane integrity and selectively targeting Gram-positive organisms due to their exposed peptidoglycan layers. Sulfated glycosaminoglycans within the cartilage matrix may interact with cell surface proteoglycans and inhibit pro-inflammatory signaling cascades, including NF-κB pathway modulation. The cytotoxic activity observed against HL60 leukemia cells is hypothesized to involve apoptosis induction, potentially through mitochondrial pathway activation, though the precise molecular targets remain uncharacterized in peer-reviewed literature.

Scientific Research

No human clinical trials exist for stingray cartilage supplements. Available research consists exclusively of in vitro studies including antimicrobial and anti-proliferative effects in cell cultures (PMID: 29104260) and isolation of antibacterial phospholipase A2 enzyme (PMID: 22956299). All evidence remains at the preliminary laboratory stage with no human efficacy or safety data.

Clinical Summary

All current evidence for stingray cartilage is limited to in vitro laboratory studies, with no randomized controlled trials or human clinical data published to date. A study indexed under PMID 22956299 demonstrated antimicrobial activity of PLA2 fractions against Gram-positive bacterial strains under controlled laboratory conditions. Separate in vitro research documented selective cytotoxic effects against HL60 human promyelocytic leukemia cells, with preliminary data suggesting relative sparing of non-cancerous cell lines, though effect sizes and concentration thresholds have not been validated in animal or human models. The overall evidence base is nascent, and any therapeutic extrapolation to human health outcomes would be premature and unsupported.

Nutritional Profile

Stingray cartilage (Dasyatis pastinaca) is a connective tissue matrix composed predominantly of protein (collagen-rich, estimated 50-70% dry weight), glycosaminoglycans (GAGs), and mineralized hydroxyapatite. Key macronutrient and bioactive compound details: **Proteins & Enzymes:** Primarily Type II collagen and collagen-derived peptides (hydroxyproline content ~8-12% of total amino acids, indicative of high collagen proportion); contains phospholipase A2 (PLA2) with demonstrated antimicrobial catalytic activity (PMID: 22956299); chitinase enzyme activity documented at 50-200 nmol/mL·h in dose-dependent manner; acid-soluble collagen (ASC) and pepsin-soluble collagen (PSC) extractable fractions are rich in glycine (~33%), proline (~12%), and hydroxyproline (~10%). **Glycosaminoglycans (GAGs):** Chondroitin sulfate (estimated 5-15% dry weight of cartilage matrix, typical of elasmobranch cartilage); smaller amounts of hyaluronic acid and keratan sulfate likely present. **Minerals:** Calcium (from hydroxyapatite, estimated 5-15% dry weight depending on calcification degree); phosphorus (Ca:P ratio approximately 1.6-2.1:1); trace amounts of magnesium, zinc, and manganese associated with cartilage matrix metalloproteinases. **Lipid fraction:** Minor component (<5% dry weight), but notable for bioactive phospholipids serving as PLA2 substrates; omega-3 polyunsaturated fatty acids (EPA/DHA) may be present in trace amounts within membrane phospholipids. **Bioactive peptides:** Upon enzymatic hydrolysis, cartilage yields low-molecular-weight peptides (typically 1-10 kDa) with reported antioxidant (DPPH/ABTS radical scavenging) and ACE-inhibitory potential, though specific IC50 values for D. pastinaca cartilage hydrolysates require further characterization. **Vitamins:** No significant vitamin content documented; trace amounts of fat-soluble vitamins (A, D, E) may be present in residual tissue but are not a meaningful dietary source. **Bioavailability notes:** Raw cartilage matrix has low digestibility due to cross-linked collagen and calcified structure; enzymatic hydrolysis (pepsin, trypsin, or alkaline protease treatment) substantially improves peptide bioavailability and bioactivity. Chondroitin sulfate oral bioavailability is generally estimated at 10-20% in humans (extrapolated from mammalian CS studies). Collagen peptides (particularly di- and tripeptides containing hydroxyproline) show relatively high oral absorption (~90% for low-MW hydrolysates). Mineral bioavailability from hydroxyapatite form is moderate compared to ionic calcium supplements. Overall, stingray cartilage is not consumed as a conventional food but is investigated as a source of bioactive protein hydrolysates, GAGs, and enzymes with potential nutraceutical applications.

Preparation & Dosage

No clinically studied dosage ranges exist for stingray cartilage in humans. Laboratory studies used enzyme concentrations of 2.5-10 μg/μL, but these cannot be translated to human supplement recommendations. No standardized extract formulations or established dosing protocols have been identified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Shark cartilage, glucosamine, chondroitin, marine collagen, astaxanthin

Safety & Interactions

No formal human safety studies, toxicology profiles, or standardized dosing guidelines exist for stingray cartilage supplements, making risk assessment highly uncertain. Individuals with seafood or shellfish allergies may face cross-reactive hypersensitivity risks due to shared marine glycoprotein antigens. Potential interactions with anticoagulant medications such as warfarin are theoretically plausible given the sulfated glycosaminoglycan content, which structurally resembles heparin, though no interaction studies have been performed. Stingray cartilage supplementation is not recommended during pregnancy, breastfeeding, or in immunocompromised individuals due to the complete absence of safety data in these populations.